r β-Adrenergic receptor agonists such as isoproterenol induce cutaneous vasodilatation and sweating in humans, but the mechanisms underpinning this response remain unresolved.
Introduction
Administration of β-adrenergic receptor agonists such as isoproterenol has been shown to induce cutaneous vasodilatation (Crandall et al. 1997; Medow et al. 2007; Hodges et al. 2015) and sweating (Sato & Sato, 1984b; Shamsuddin et al. 2008; Quinton et al. 2012) under normothermic resting conditions in humans. However, the mechanisms underlying these responses are largely unknown. Studies have shown that nitric oxide synthase (NOS) and cyclooxygenase (COX) can contribute to the regulation of cutaneous blood flow (Shastry et al. 2000; Holowatz et al. 2005; McCord et al. 2006; Medow et al. 2007; Hojs et al. 2009; McNamara et al. 2014 ) and sweating (Lee & Mack, 2006; Fujii et al. 2014; Stapleton et al. 2014) . However, no study has evaluated whether NOS and COX are involved in the β-adrenergic cutaneous vasodilatation and sweating.
In general, β-adrenergic receptor activation stimulates adenylate cyclase thereby causing a rise in cAMP, a second messenger. cAMP in turn activates protein kinase A, modulating several cellular processes. If this response occurs in the vascular smooth muscle cells, it would result in vasorelaxation as it reduces Ca 2+ bioavailability. This is thought to be a main mechanism mediating β-adrenergic vasodilatation. However, β-adrenergic receptors are also found on endothelial cells (Howell et al. 1988; O'Leary et al. 2015) , highlighting the possibility that endothelium-dependent factors (i.e. NOS, COX, and/or endothelium-dependent hyperpolarization) are involved in β-adrenergic vasodilatation. Indeed, in human forearm conduit arteries, NOS has been shown to contribute to vasodilatation associated with β-adrenergic receptor activation (Cardillo et al. 1997; Casey et al. 2011) . NOS-derived NO induces vasodilatation through a soluble guanylyl cyclase-dependent increase in cGMP, another second messenger (Kellogg et al. 2011) . Furthermore, a recent study by Limberg et al. (2016) demonstrated that COX activation has an opposing effect by restraining β-adrenergic vasodilatation in the human forearm conduit artery. These responses may remain intact in cutaneous vasculature.
It has been shown that β-adrenergic sweating is mediated via elevating cAMP in the sweat glands (Sato & Sato, 1984b; Shamsuddin et al. 2008) . Since COX-derived prostanoids can increase cAMP (O'Keefe et al. 1992; Smyth et al. 2009) , it is plausible that COX may contribute to the β-adrenergic sweating. In addition, NOS in sweat glands (Shimizu et al. 1997) may be stimulated by β-adrenergic receptor activation, as observed in the above-mentioned studies using human conduit artery (Cardillo et al. 1997; Casey et al. 2011) , and this ultimately would induce an increase in cGMP. However, an earlier study reported that elevations in cGMP did not directly increase sweat rate in eccrine sweat glands of the monkey palm under in vitro conditions (Sato & Sato, 1984a) . Furthermore, administration of an NO donor in the forearm skin did not increase sweat rate in normothermic resting humans in vivo . Based on these findings, an NOS-induced increase in NO, if any, may not be involved in β-adrenergic sweating.
The purpose of this study was to evaluate whether NOS and COX modulate β-adrenergic cutaneous vasodilatation and sweating in humans. We hypothesized that NOS contributes to β-adrenergic cutaneous vasodilatation, but COX limits this response. We also hypothesized that COX, but not NOS, is involved in β-adrenergic sweating. As a secondary objective of our study, we evaluated if β-adrenergic cutaneous vasodilatation is diminished by repeated activation of β-adrenergic receptors as was observed for β-adrenergic sweating (Sato et al. 1991) . Furthermore, to date, there are no studies evaluating mechanisms underlying the diminished β-adrenergic responses in human skin. We explored whether the diminished β-adrenergic sweating and cutaneous vasodilatation, if any, are associated with NOS and COX. The results obtained in this study would provide important clinical insights. β-Adrenergic vasodilatation typically measured in the forearm is often used to evaluate conduit artery vascular function (Stein et al. 1995; Cardillo et al. 1997; Harvey et al. 2014) . Our result provides important new insights on the potential use of β-adrenergic cutaneous vasodilatation to evaluate microvascular function, the dysfunction of which is associated with cardiovascular disease (Abularrage et al. 2005) .
Methods

Ethical approval
This study was approved by the University of Ottawa Health Sciences and Science Research Ethics Board, conforming to the guidelines set forth by the Declaration of Helsinki. Verbal and written informed consent was obtained from all volunteers before their participation in this study.
Participants
Ten young physically active males participated in the current study. The participants physical characteristics were as follows (mean ± SD); age: 25 ± 5 years, height: 1.73 ± 0.07 m, body mass: 69.6 ± 7.9 kg, and body mass index: 23.2 ± 2.0. All participants had a normal resting blood pressure (i.e. systolic pressure: 113 ± 6 mmHg, diastolic pressure: 75 ± 6 mmHg, and mean arterial pressure: 88 ± 5 mmHg). Body height was measured using an eye-level physician stadiometer (Model 2391, Detecto Scale Company, Webb City, MO, USA), body mass was measured using a digital weight scale platform (Model CBU150X, Mettler Toledo Inc., Columbus, OH, USA) and blood pressure was obtained by a mercury column sphygmomanometer (Baumanometer Standby Model, WA Baum Co. Inc., Copiague, NY, USA). None of the participants had a history of chronic health conditions (cystic fibrosis transmembrane conductance regulator mutations, skin disorders, hypertension, heart disease, diabetes or autonomic disorders) and none were taking prescription medication. All participants were non-smokers.
Main experimental trial
All participants were instructed to abstain from taking non-steroidal anti-inflammatory drugs, vitamins, minerals and over-the-counter medications for a minimum of 48 h prior to the start of the main experimental trial. They were also required to refrain from consuming alcohol and caffeine, as well as performing strenuous physical activity at least 12 h before the start of the experimental trial. Participants were permitted to consume a light meal at least 2 h prior to arriving at the laboratory. Upon arrival in the laboratory, the participants provided a urine sample, which was analysed by a handheld total solids refractometer (Model TS400, Reichter Inc., Depew, NY, USA). Participants were considered euhydrated [i.e. urine specific gravity of 1.019 ± 0.004 (Sawka et al. 2007) ]. Participants subsequently rested in a semi-recumbent upright position on a bed in a thermoneutral environment (room temperature of 23-25°C). During this time, a 25-gauge needle was inserted into the dermal layer of the dorsal forearm skin using an aseptic technique with the entry and exit points separated by ß2.5 cm. A microdialysis fibre (30 kDa cutoff, 10 mm membrane) (MD2000, Bioanalytical Systems, West Lafayette, IN, USA) was thereafter passed through the lumen of the needle. The needle was subsequently withdrawn leaving the fibre in the skin. This process was duplicated until four microdialysis fibres were implanted in the skin. Each fibre was separated by >4 cm to avoid drug interference between sites. Each fibre was connected to the outlet port of a liquid switch (Model 110, CMA Microdialysis AB, Kista, Sweden).
At approximately 10 min after placement of the microdialysis fibres, four microdialysis fibres were continuously perfused with (1) lactated Ringer solution (Baxter, Deerfield, IL, USA) (Control), (2) 10 mM N ω -nitro-L-arginine (L-NNA, Sigma-Aldrich, St Louis, MO, USA) to non-selectively inhibit NOS, (3) 10 mM ketorolac (Sigma-Aldrich) to non-selectively inhibit COX, and (4) a combination of 10 mM L-NNA + 10 mM ketorolac. These solutions were perfused for ࣙ75 min to establish the effects of each agent. All agents were dissolved in lactated Ringer solution with 4 mM theophylline (Sigma-Aldrich) to clearly establish a β-adrenergic sweating (see below for details). The concentration for each drug was determined based on previous reports employing intradermal microdialysis in human skin for L-NNA (Medow et al. 2007) , ketorolac (Holowatz et al. 2005) and theophylline (Fieger & Wong, 2010) . Perfusion at each of the skin sites was maintained at a rate of 4.0 μl min −1 using a micro infusion pump (Model 4004, CMA Microdialysis, Solna, Sweden).
Following the ࣙ 75 min infusion of each inhibitor, baseline measurements were acquired for at least 10 min (Baseline). The infusion of 100 μM isoproterenol, a non-selective β1-and β2-adrenergic receptor agonist (Sigma-Aldrich), was subsequently performed at a rate of 4.0 μl min −1 for 3 min at each of the sites which elicited cutaneous vasodilatation and sweating (Fig. 1) . After the β-adrenergic cutaneous vasodilatation and sweating (ß60 min after the administration) had subsided and responses returned to Baseline levels for at least 5 min, 1, 10 and 100 μM isoproterenol were then administered in an ascending order for 25 min for each of the three concentrations. Since repeated isoproterenol administration results in abolished β-adrenergic sweating (Sato et al. 1991) , the 3 min administration of a high dose of isoproterenol (100 μM) preceded the incremental administration of isoproterenol to maximally evoke β-adrenergic sweating at the start. All isoproterenol solutions were dissolved in lactated Ringer solution with 4 mM theophylline as with the baseline solutions (NOS and/or COX inhibitor) made without isoproterenol (see above). The addition of theophylline was required as the use of the β-adrenergic receptor agonist alone is insufficient to increase cAMP to levels that would be required to induce sweating due to phosphodiesterase, which degrades cAMP. Theophylline is a phosphodiesterase inhibitor and when infused in combination with a β-adrenergic receptor agonist, it can sufficiently elevate cAMP, thereby inducing sweating (Sato & Sato, 1984b; Shamsuddin et al. 2008) . To minimize the risk of potential palpitations associated with systemic circulation of isoproterenol (Sato & Sato, 1984b) , we opted not to use concentrations of isoproterenol greater than 100 μM.
After completion of all isoproterenol administrations, 50 mM sodium nitroprusside (Sigma-Aldrich) dissolved in lactated Ringer solution was administered at each microdialysis site at a rate of 6.0 μl min −1 . This administration continued for 20-30 min until a stable plateau of cutaneous blood flow was established over a minimum 2 min period.
Supplementary experimental trial
As mentioned above, we employed theophylline to induce β-adrenergic sweating in our main experimental trial. However, theophylline is known to block adenosine J Physiol 595.4 receptors in human forearm skin (Fujii et al. 2015) . Therefore, the observed β-adrenergic cutaneous vasodilatation and sweating with theophylline may have been influenced by adenosine-mediated mechanisms. To elucidate this possibility, we performed a supplementary experimental trial. Nine young physically active males participated and their physical characteristics were as follows (mean ± SD): age: 26 ± 5 years, height: 1.71 ± 0.06 m, body mass: 77.7 ± 15.7 kg, and body mass index: 26.6 ± 5.8. Resting mean arterial pressure was 89 ± 8 mmHg with systolic and diastolic pressures of 116 ± 9 and 75 ± 9 mmHg, respectively. All participants were euhydrated prior to the start of the experimental trial as defined by a urine specific gravity of 1.012 ± 0.003 (Sawka et al. 2007 ). The protocol procedures and timeline were as outlined above for the main experimental trial with the exception that two microdialysis fibres were continuously perfused with either (1) lactated Ringer solution (Control) or (2) 10 mM L-NNA to non-selectively inhibit NOS. A 10 min baseline measurement period was performed followed by co-administration of 9 mM adenosine (Sigma-Aldrich) at the two sites over a 3 min period (Fig. 2) . After the observed increase in cutaneous blood flow elicited by adenosine had subsided, we co-infused 100 μM isoproterenol for 25 min for both sites (Fig. 2) . In contrast to the main experimental trial, theophylline was not employed. Our observation of a lack of an increase in sweat rate induced by the administration of isoproterenol without theophylline ( Fig. 2B ) provides strong support for the inclusion of theophylline in our main experimental trial to detect β-adrenergic sweating.
Measurements
Cutaneous red blood cell flux, an index of cutaneous blood flow expressed in perfusion units, was measured at a sampling rate of 32 Hz with laser-Doppler flowmetry (PeriFlux System 5000, Perimed, Stockholm, Sweden). Integrated laser-Doppler flowmetry probes with a seven-laser array (Model 413, Perimed) were placed in the centre of each sweat capsule (see below for details) over each microdialysis fibre. Systolic and diastolic blood pressures were manually obtained every 10-15 min using a mercury column sphygmomanometer (WA Baum Co. Inc.). Mean arterial pressure was calculated as diastolic arterial pressure plus one-third the difference between systolic and diastolic pressures. Cutaneous vascular conductance (CVC) was evaluated as cutaneous red blood cell flux divided by mean arterial pressure, and was presented in %max using maximal absolute CVC obtained during sodium nitroprusside administration. Representing CVC in %max was necessary to minimize the effect of site-to-site heterogeneity on the level of cutaneous blood flow (Minson, 2010) . Heart rate was estimated from a pulsatile waveform of cutaneous red blood cell flux in the main experimental trial.
Sweat capsules designed for use with intradermal microdialysis (surface area: 1.1 cm 2 ) (Meade et al. 2016) were placed directly over the centre of each microdialysis membrane. The sweat capsules were secured to the skin with adhesive rings and topical skin glue (Collodion HV, Mavidon Medical products, Lake Worth, FL, USA). Dry compressed air in a gas tank located within the testing room maintained at 23-25°C was supplied to each capsule at a rate of 0.20 l min −1 . High-precision dew point mirrors (Model 473, RH Systems, Albuquerque, NM, USA) were employed to assess the water content of the effluent air from the sweat capsule. Long vinyl tubes were employed for connections between the gas tank and the sweat capsule, and between the sweat capsule and the dew point mirror. Local forearm sweat rate was calculated every 5 s based on the difference in water content between influent and effluent air, which was expressed as sweat rate per skin surface area under the capsule (mg min −1 cm −2 ).
Data analysis
For the main experimental trial, baseline CVC and sweat rate (as assessed prior to the administration of isoproterenol) were obtained by averaging values over the final 5 min (Baseline). During the first 100 μM isoproterenol administration, peak CVC was evaluated as the highest CVC over 5 min. During the subsequent incremental isoproterenol administration (1, 10, 100 μM isoproterenol), CVC was evaluated by averaging values over the last 5 min of each dose administration. The above CVC during each isoproterenol administration was presented as change ( ) in CVC from Baseline (original baseline before commencing the isoproterenol infusion protocol). Due to technical difficulty, we were not able to obtain CVC during the first 100 μM isoproterenol administration in one subject (i.e. n = 9). At each dose of isoproterenol administered, sweat rate was evaluated as the 1 min peak value. As with CVC, sweat rate during isoproterenol administration was presented as sweat rate from 1 min baseline (i.e. baseline obtained immediately before initiation of β-adrenergic sweating at each dose). We used shorter average data for sweat rate (i.e. 1 min) compared to CVC (5 min) as β-adrenergic sweating is relatively transient (Fig. 1B) . NOS inhibition-induced CVC in relation to the Control site during each 100 μM isoproterenol administration was evaluated to determine an NOS component of β-adrenergic cutaneous vasodilatation.
In the supplementary experimental trial, baseline CVC and sweat rate (as assessed prior to the administration of adenosine) were obtained by averaging values over the final 5 min (Baseline). During the 9 mM adenosine administration, peak CVC was evaluated as the highest CVC over 5 min. During the subsequent 100 μM isoproterenol administration, CVC was evaluated by averaging values over the last 5 min. Each CVC value was presented as the change ( ) in CVC from Baseline (original baseline before commencing adenosine infusion). As with the main experimental trial, NOS inhibition-induced CVC in relation to the Control site during the 100 μM isoproterenol administration was obtained as an index of the NOS component for β-adrenergic cutaneous vasodilatation.
Statistical analysis
Statistical analyses were performed with the software package SPSS 23 for Windows (IBM, Armonk, NY, USA). A two-way, repeated measures analysis of variance was used to analyse CVC and sweat rate obtained in the main experimental trial with the factors of treatment site (Control, NOS inhibition, COX inhibition, NOS + COX inhibition) and stage (Baseline, isoproterenol administration of 100, 1, 10 and 100 μM). In the main experimental trial, a one-way, repeated measures analysis of variance was used for CVC and sweat rate obtained during Baseline as well as maximal absolute CVC measured during sodium nitroprusside administration with the factor of treatment site (Control, NOS inhibition, COX inhibition, NOS + COX inhibition). A one-way analysis of variance with non-repeated factor was employed for NOS inhibition-induced CVC relative to the Control site during each 100 μM isoproterenol administration (first and second responses with theophylline and one response without theophylline). When a significant interaction or a main effect was detected, subsequent post hoc comparisons were performed using Student's paired two-tailed (between-site comparisons) or one-tailed (compared to Baseline within a site) t tests. The P value for post hoc comparisons was adjusted using a Hochberg's procedure (Hochberg, 1988) , a modified version of Bonferroni correction. We elected to use this modified Bonferroni correction that is less conservative than the original one, as the original Bonferroni correction is considered overly conservative such that it can increase type II errors (Perneger, 1998) . One-tailed t tests were used to test (1) whether CVC and sweat during the second 100 μM isoproterenol administration were lower than those during the first administration in the main experimental trial; (2) if CVC obtained during adenosine administration differed between the Control and NOS inhibition sites in the supplementary experimental trial; and (3) whether adenosine directly increased sweat rate from Baseline in the supplementary experimental trial. Two-tailed t tests were also used to evaluate whether heart rate, and systolic, diastolic and mean arterial pressure measured during Baseline differed from those obtained during the last 1 min of the second 100 μM isoproterenol administration in the main experimental trial. The level of significance for all analyses was set at P ࣘ 0.05. All values are reported with a mean ± 95 % confidence interval (1.96 × SEM).
Results
Cutaneous vasodilatation
For the main experimental trial, CVC during Baseline (Table 1 ) and maximal absolute CVC during sodium nitroprusside administration did not differ between sites (all P > 0.26). CVC obtained at the Control site increased in response to administration of all isoproterenol doses used in the present study (all P ࣘ 0.05, Figs 1A and  3A) . During the first and second 100 μM isoproterenol administration, NOS inhibition alone lowered (all P ࣘ 0.05), but did not abolish (i.e. CVC was greater than Baseline, all P ࣘ 0.05), cutaneous vasodilatation (Fig. 3A) . In contrast, COX inhibition alone augmented cutaneous vasodilatation during the 10 μM and second 100 μM isoproterenol administration (both P ࣘ 0.05, Fig. 3A ). Combined inhibition of NOS and COX attenuated cutaneous vasodilatation at all doses of isoproterenol infused, and isoproterenol-induced cutaneous vasodilatation was abolished during the 1, 10 and second 100 μM isoproterenol administration (i.e. CVC was not higher than Baseline, all P > 0.05, Fig 3A) . At all four skin sites, CVC was smaller during the second relative to the first 100 μM isoproterenol administration (Table 2 ).
In the supplementary experimental trial, adenosine increased CVC at both Control and NOS inhibition sites, and CVC during adenosine administration was reduced by NOS inhibition (all P ࣘ 0.05, Figs 2A and 3B) . The NOS component of β-adrenergic cutaneous vasodilatation without the co-administration of theophylline did not differ from that observed with the co-administration of theophylline (all P > 0.98, Fig. 4) . Furthermore, this reduction in CVC associated with NOS inhibition did not differ between the first and second 100 μM isoproterenol administration periods in the presence of theophylline (P > 0.98, Fig. 4 ).
Sweating
In the main experimental trial, sweat rate during Baseline was not different between sites (all P > 0.46, Table 1 ). At the Control site, the first 100 μM isoproterenol administration increased sweating (P = 0.02), but subsequent isoproterenol infusions failed to induce a significant increase in sweating (all P > 0.12) (Fig. 1B) . Although neither NOS nor COX inhibition alone modulated isoproterenol-induced sweating (all P > 0.40), a simultaneous inhibition of NOS and COX augmented the response relative to Control during the first 100 μM isoproterenol administration (P = 0.05, Fig. 5A ). At all four skin sites, sweat rate was smaller during the second vs. first 100 μM isoproterenol administration (all P ࣘ 0.05, Table 2 ). Adenosine infused in the supplementary experimental trial did not increase sweat rate at the Control site (P = 0.10, Figs 2B and 5B).
Heart rate and blood pressure
In the main experimental trial, there was no difference between Baseline (before initiating isoproterenol administration protocol) and the last 1 min of the second 100 μM isoproterenol administration for heart rate (60 ± 6 vs. 62 ± 5 beats min −1 , P = 0.28), or systolic (114 ± 4 vs. 113 ± 4 mmHg, P = 0.53), diastolic (75 ± 4 vs. 76 ± 4 mmHg, P = 0.31) and mean (88 ± 3 vs. 88 ± 3 mmHg, P = 0.40) arterial pressure.
Discussion
The present study demonstrated that in young adults, NOS inhibition attenuated β-adrenergic cutaneous vasodilatation, whereas COX inhibition augmented β-adrenergic cutaneous vasodilatation. Furthermore, we showed that a combined inhibition of NOS and COX enhanced β-adrenergic sweating.
Cutaneous vasodilatation
We showed that NOS largely (ß50%) contributes to β-adrenergic cutaneous vasodilatation at the first and second administration of 100 μM isoproterenol (Fig. 3A , Table 2 ); this influence is consistent with previous reports in human conduit artery studies (Cardillo et al. 1997; Casey et al. 2011) . The mechanism(s) underpinning this response cannot be fully elucidated from the present et al. 2015) . The β2-adrenergic receptor activation may stimulate NOS-derived NO production in the human skin, as previously observed in human conduit artery in vivo (Dawes et al. 1997) and human umbilical vein endothelium in vitro (Ferro et al. 1999) .
In the present study, COX inhibition augmented β-adrenergic cutaneous vasodilatation in the final two concentrations of isoproterenol infusion (i.e. the 10 μM and second 100 μM) (Fig. 3A) . This result indicates that activation of COX restrains β-adrenergic cutaneous vasodilatation. This is supported by a similar pattern of response observed in human conduit artery in vivo (Limberg et al. 2016) . Furthermore, although not β-adrenergic cutaneous vasodilatation, the COX-dependent limiting effect on cutaneous perfusion has also been observed during (1) the reactive hyperaemia observed following a period of arterial occlusion of the forearm in young adults (Medow et al. 2007; Cavka et al. 2015) and (2) normothermic resting in middle-aged adults (Holowatz et al. 2009 ). COX-derived vasoconstrictor prostanoids(s) may be selectively produced during β-adrenergic receptor activation, restraining β-adrenergic cutaneous vasodilatation. In this regard, COX converts arachidonic acid to prostaglandin H2, which itself can yield a vasoconstrictor effect. Prostaglandin H2 can be further converted to different prostanoids such as prostacyclin and thromboxane A2, the latter of which is known to cause vasoconstriction. Hence, prostaglandin H2, thromboxane A2 and/or other vasoconstrictor prostanoids(s) is/are potentially involved in the limiting effect of COX on β-adrenergic cutaneous vasodilatation. During the first 100 μM isoproterenol administration, isoproterenol-induced cutaneous vasodilatation was not abolished by a combined inhibition of NOS and COX (Table 2) . Thus, a portion of β-adrenergic cutaneous vasodilatation can occur independently of NOS and COX; this could be attributed to an endothelium-independent mechanism. That is, direct activation of β-adrenergic receptors located on vascular smooth muscle cells activates adenylyl cyclase, leading to an elevation in cAMP and in turn vasodilatation. Alternatively, potassium channels may be involved in the non-NOS and COX component of β-adrenergic cutaneous vasodilatation. Isoproterenol has been shown to induce vasodilatation associated with activation of ATP-sensitive potassium (K ATP ) channels in vascular smooth muscle cells of rat mesenteric arteries in vitro (Garland et al. 2011) . It is therefore possible that a similar mechanism may be involved in the β-adrenergic cutaneous vasodilatation in human skin in vivo. Also, it is important to highlight the fact that in contrast to the β-adrenergic cutaneous vasodilatation measured during the first 100 μM isoproterenol administration, the β-adrenergic cutaneous vasodilatation during the subsequent isoproterenol administration (1, 10, 100 μM) was abolished at the NOS + COX inhibition site (Fig. 3A) . Hence, it appears that the subsequent β-adrenergic cutaneous vasodilatation is greatly associated with activities of NOS and COX.
Sweating
The first 100 μM isoproterenol administration increased sweat rate at all skin sites in the present study (Figs 1B and 5A) , which is probably the result of activation of the β2 receptor, a receptor sub-type that is dominant in human eccrine sweat glands (Steinkraus et al. 1996) . Upon activation of β-adrenergic receptors, there is an increase in cAMP in sweat glands (Sato & Sato, 1984b) . When this β-adrenergic increase in cAMP was augmented by administration of phosphodiesterase inhibitor, β-adrenergic sweating was also markedly augmented, as observed in the present (Figs 1B and 2B) and previous studies (Sato & Sato, 1984b) . Thus, it appears that β-adrenergic sweating is largely due to cAMP-dependent mechanisms. Of importance, we show that a combined inhibition of NOS and COX augmented β-adrenergic sweating induced by the initial 100 μM isoproterenol administration (Fig. 5A ). This response seems to be associated with alteration in cAMP bioavailability. Indeed, NO can reduce cAMP as observed in rat aorta (Kang et al. 2007) ; similarly, prostanoid-induced activation of the EP3 receptor (one of the prostaglandin receptors) leads to a decrease in cAMP (Hatae et al. 2002) . However, it is important to note that neither NOS nor COX inhibition alone augmented β-adrenergic sweating (Fig. 5A) , supporting the possibility of an interactive influence of both enzymes (Salvemini et al. 2013) . If NOS and COX inhibit each other, while the inhibition of NOS alone can increase cAMP by removing NO-induced reduction in cAMP (Kang et al. 2007) , NOS inhibition simultaneously decreases cAMP by unmasking its inhibitory effect on COX-induced EP3 receptor-dependent reduction in cAMP (Hatae et al. 2002) . As a consequence, levels of cAMP availability are unaffected, thereby resulting in no change in β-adrenergic sweating. A comparable response can occur with the inhibition of COX only. However, inhibiting both NOS and COX would eliminate both their inhibitory effects on cAMP, thereby augmenting cAMP levels and β-adrenergic sweating.
β-Adrenergic regulation of cutaneous vasodilatation and sweating
In this study, we observed a different pattern of response between the β-adrenergic regulation of cutaneous vasodilatation and sweating. Although β-adrenergic receptor activation with isoproterenol stimulated both cutaneous vasodilatation and sweating, β-adrenergic-mediated changes in sweating were brief whereas the response for cutaneous vasodilatation was more enduring (Fig. 1) . Furthermore, simultaneous inhibition of NOS and COX abolished β-adrenergic cutaneous vasodilatation (Fig. 3A) while it augmented β-adrenergic sweating (Fig. 5A ). These disparate responses could reflect differential signalling mechanisms governing β-adrenergic cutaneous vasodilatation and sweating. As discussed above, cAMP appears to play a pivotal role in β-adrenergic sweating.
In terms of the regulation of cutaneous perfusion, our results indicate that NOS is a major mechanism mediating β-adrenergic cutaneous vasodilatation (Fig. 3A) . NO produced from NOS can activate soluble guanylyl cyclase, thereby increasing cGMP, which can ultimately cause vasodilatation (Kellogg et al. 2011) . Therefore, β-adrenergic cutaneous vasodilatation appears to be associated with not only cAMP but also cGMP, and possibly other mechanisms such as K ATP channels as noted above.
Adenosine mechanisms
We used theophylline to maximize the increase in cAMP associated with isoproterenol administration and thus β-adrenergic sweating. However, theophylline is also known to block adenosine receptors in human skin as adenosine-induced cutaneous vasodilatation is largely diminished by theophylline (Fujii et al. 2015) . Isoproterenol may induce vasodilatation through increases in adenosine (Tanaka et al. 1990) , and adenosine may activate NOS (Nyberg et al. 2010) . We also demonstrated for the first time that adenosine-induced cutaneous vasodilatation is partly a result of NOS-dependent mechanisms (Fig. 3B) . Hence one might speculate that the NOS component of β-adrenergic cutaneous vasodilatation observed with theophylline is partly influenced by mechanisms mediated by adenosine. However, this is not likely as our results clearly indicate that the magnitude of the NOS component of β-adrenergic cutaneous vasodilatation is not influenced by theophylline (Fig. 4 ). An additional novel finding of our study was that adenosine did not directly increase sweat rate (Fig. 5B) . Therefore, any increase in sweat rate associated with β-adrenergic receptor activation should be adenosineindependent.
Altered β-adrenergic responses with repeated activation
We observed the magnitude of β-adrenergic sweating was smaller during the second vs. the first 100 μM isoproterenol administration (Table 2) , which is in accordance with a previous report (Sato et al. 1991) . Furthermore, we demonstrated for the first time that β-adrenergic cutaneous vasodilatation was also smaller during the second relative to the first 100 μM isoproterenol administration (Table 2) . Therefore, irrespective of the end-organ type (i.e. sweat glands, skin vessels), β-adrenergic response is diminished with repeated activation. This is an interesting observation, as skin vessels and sweat glands are entirely different regarding structure (endothelial and vascular smooth muscle cells in the skin vessels vs. secretary cells in sweat glands) and function (regulation of vascular tone vs. secretion of sweat). It may be that β-adrenergic receptors, which are located on both skin vessels and sweat glands, become desensitized with repeated activation leading to an attenuated increase in cAMP. As a consequence, this leads to a reduced activation of the end-organ without a change in end-organ sensitivity to cAMP. Further study is required to elucidate this possibility.
To the best of our knowledge, this is the first study to evaluate the underlying mechanisms of diminished β-adrenergic cutaneous vasodilatation and sweating with repeated activation of β-adrenergic receptors. We showed that the diminished β-adrenergic cutaneous vasodilatation and sweating occurred independently of NOS and COX, as all four skin sites showed similar attenuations (Table 2 ). In line with this, the NOS contribution of β-adrenergic cutaneous vasodilatation remained intact with repeated activation of β-adrenergic receptors (Fig. 4) . However, our results indicate that repeated activation of β-adrenergic receptors alters COX-dependent mechanisms underlying β-adrenergic cutaneous vasodilatation. Indeed, although COX inhibition alone did not affect β-adrenergic cutaneous vasodilatation during the first 100 μM isoproterenol administration, it augmented β-adrenergic cutaneous vasodilatation during the subsequent isoproterenol administration (Fig. 3A, Table 2 ). Additionally, while COX inhibition combined with NOS inhibition did not abolish β-adrenergic cutaneous vasodilatation during the first 100 μM isoproterenol administration, it abolished the vasodilatation during the subsequent isoproterenol administration (Fig. 3A, Table 2 ). It is plausible that these responses may be a result of desensitization and/or downregulation of β1-and β2-adrenergic receptors (Hausdorff et al. 1990; Thomas et al. 1992) and/or upregulation of β3-adrenergic receptors (Thomas et al. 1992 ) that can occur during repeated administration of β-adrenergic receptor agonist.
Considerations
In the present study we limited our evaluation to males only given some important sex-related differences. First, we used young males only since previous work showed that males exhibit a greater β-adrenergic sweating response relative to their female counterparts (Quinton et al. 2012) . Secondly, NOS-and COX-dependent mechanisms involved in β-adrenergic forearm vasodilatation have been shown to differ between males and females (Limberg et al. 2016) . Thus, there may be sex-related differences in the underlying mechanism(s) associated with β-adrenergic cutaneous vasodilatation and possibly sweating. Further studies are warranted to determine if the pattern of response observed in the males of the present study may differ from those in females.
Clinical significance
Cutaneous vascular response can be used to evaluate microvascular function. Evaluating microvascular function is important as microcirculatory dysfunction may lead to cardiovascular disease (Abularrage et al. 2005) . Our results demonstrated that NOS is a major player in β-adrenergic cutaneous vasodilatation, suggesting that β-adrenergic cutaneous vasodilatation may be a useful tool to evaluate microvascular function associated with NOS.
Conclusion
We demonstrate that in young adults, NOS contributes to β-adrenergic cutaneous vasodilatation, while COX restrains this vasodilatation. We also demonstrate that blocking the action of both NOS and COX augments β-adrenergic sweating.
